D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis.
Psychopharmacology. 2014-03-06; 231(18): 3765-3770
DOI: 10.1007/s00213-014-3516-3
Read on PubMed
1. Psychopharmacology (Berl). 2014 Sep;231(18):3765-70. doi:
10.1007/s00213-014-3516-3. Epub 2014 Mar 6.
D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic
drugs in obsessive-compulsive disorders: a metaregression analysis.
Ducasse D(1), Boyer L, Michel P, Loundou A, Macgregor A, Micoulaud-Franchi JA,
Courtet P, Abbar M, Leboyer M, Fond G.
Author information:
(1)INSERM U1061, Université Montpellier 1, Service Universitaire de Psychiatrie
Urgence et Post-urgence, CHU Montpellier, Montpellier, 34000, France.
RATIONALE AND OBJECTIVE: The relationship between clinically effective
antipsychotic drugs in obsessive-compulsive disorders (OCD) and binding
affinities to cloned dopamine and serotonin receptor subtypes was analyzed in an
effort to clarify the contribution of individual receptor subtypes to medication
response.
METHODS: Meta-analysis was used to update previous meta-analyses of effectiveness
data of add-on antipsychotic drugs to selective serotonin reuptake inhibitors
(SSRIs) in OCD. Twelve previously analyzed randomized controlled trials (RCTs)
and one new RCT were included. We performed a metaregression using a mixed-effect
model to examine the association between antipsychotic’s effectiveness and
receptor affinity.
RESULTS: A total of 5 treatment arms obtained from 13 RCTs (431 patients) were
included in our study. The results of our metaregression showed a significant
association between D2 and D3 dopamine receptor affinities and effectiveness in
OCD (respectively, slope = -0.36, p = 0.01; and slope = -0.50, p = 0.01) whereas
other dopamine receptors and serotonin receptors were not significantly
associated.
CONCLUSIONS: These observations suggest that increasing D2 and D3 dopamine
receptor binding affinities enhances antipsychotics’ effectiveness in
obsessive-compulsive disorders.
DOI: 10.1007/s00213-014-3516-3
PMID: 24599398 [Indexed for MEDLINE]